Advicenne Signs Agreement with Elaiapharm for Product Manufacturing

Published on: 

The supply agreement comes after an eight-year collaboration between the companies.

Advicenne, a Nîmes, France-based pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced it signed a supply agreement with Elaiapharm Lundbeck, a pharmaceutical contract manufacturing organization in Sophia Antipolis, France, for the manufacturing of its lead product, ADV7103, as a treatment for distal renal tubular acidosis (dRTA).

The prolonged-release formulation product was developed as a multi-particulate formulation in 2-mm granules that contains two active pharmaceutical ingredients to ease its administration in patients of all ages, according to a Sept. 4, 2019 press release. The drug is designed for sustained release over a 12-hour time period. 

The agreement comes after an eight-year collaboration between the companies for the development of Advicenne’s lead drug candidate.


“For years, our close working collaboration with Elaiapharm has pushed us past many challenges to make the innovative manufacturing process of ADV7103 a success,” said Caroline Roussel, co-founder and director of operations at Advicenne, in the press release. “We are very pleased to continue working as a team with Elaiapharm. Their knowledge and high-quality industrial standards are a key advantage for the commercial production of our lead candidate.”

Source: Advicenne